Haemate (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate is indicated for the management of bleeding disorders related to factor VIII and von Willebrand factor deficiencies.

• Treatment of acute bleeding episodes in patients with hemophilia A (factor VIII deficiency).
• Prophylactic replacement therapy to prevent spontaneous or trauma‑induced bleeds in hemophilia A.
• Management of bleeding and surgical prophylaxis in patients with von Willebrand disease, particularly type 3.
• Support during major surgery or invasive procedures in individuals with combined factor VIII/vWF deficiency.
• Adjunct therapy in patients undergoing dental extractions or minor procedures when hemostasis is required.

The safety profile of Haemate includes both frequently observed reactions and rare but serious events.

Common

• Mild infusion‑site reactions such as erythema, swelling, or pain.
• Transient fever or chills during or shortly after administration.
• Headache or fatigue.

Serious

• Allergic anaphylactic reactions, including urticaria, bronchospasm, or hypotension.
• Development of inhibitors (antibodies) against factor VIII or von Willebrand factor.
• Thromboembolic events such as deep‑vein thrombosis or pulmonary embolism.

Clinicians should consider several precautions when prescribing Haemate to ensure safe and effective use.

• Assess baseline factor VIII and von Willebrand activity levels before initiating therapy.
• Monitor for the development of inhibitors, especially in previously untreated patients.
• Use caution in patients with a history of allergic reactions to plasma‑derived products.
• Avoid rapid infusion rates; administer according to recommended infusion guidelines to reduce adverse reactions.
• Evaluate cardiovascular risk, as rapid correction of coagulation may increase thrombosis risk.
• Pregnancy and lactation status should be reviewed, as safety data are limited.
• Renal or hepatic impairment may affect clearance; adjust dosing as clinically indicated.

Haemate may interact with other medications that affect hemostasis or immune response.

Avoid

• Concurrent use of other pro‑coagulant agents (e.g., activated factor VII) without specialist guidance.
• Administration with investigational gene‑therapy products targeting factor VIII.

Use with caution

• Antifibrinolytic agents such as tranexamic acid may augment hemostatic effect; monitor for thrombosis.
• Immunosuppressive drugs (e.g., rituximab) may alter inhibitor development risk.
• Concomitant use of high‑dose steroids may mask allergic reactions.
• Vaccines administered shortly after infusion may have reduced efficacy; schedule appropriately.